Genmark Diagnostics (GNMK) Azione Prezzo
Genmark Diagnostics Prezzo
Il fatturato è cresciuto a un tasso composto del 59,2% annuo negli ultimi 12 anni, raggiungendo 171,55 Mio. USD. Il margine netto di Genmark Diagnostics si attesta al -10,9%, in aumento rispetto al -102,7% di alcuni anni fa.
Genmark Diagnostics Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Genmark Diagnostics Azione e analisi azionaria
Domande frequenti sull'azione Genmark Diagnostics
Genmark Diagnostics Inc. operates with a business model focused on developing molecular diagnostic solutions. The company primarily specializes in the design, manufacturing, and marketing of diagnostic testing systems. Genmark's products are engineered to deliver accurate and timely results for detecting various infectious diseases and genetic conditions. Their solutions are designed to be flexible, providing rapid and comprehensive testing capabilities for a wide range of clinical applications. With a strong emphasis on innovation and advanced technology, Genmark Diagnostics Inc. aims to provide healthcare professionals with the tools they need to enhance patient care and improve overall outcomes.
Genmark Diagnostics Inc is primarily active in the healthcare and life sciences industries.
The main competitors of Genmark Diagnostics Inc in the market include Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation, and Roche Holding AG.
Genmark Diagnostics Inc, founded in 1993, is a leading provider of molecular diagnostic solutions. It specializes in developing and commercializing multiplex molecular tests, automation platforms, and software analytics. The company's innovative solutions enable healthcare providers to quickly and accurately diagnose multiple diseases, including respiratory infections, gastrointestinal infections, and sepsis. Genmark Diagnostics Inc has a strong track record of delivering high-quality testing solutions, enabling hospitals and laboratories to improve patient care and outcomes. With a dedicated team and a commitment to advancing molecular diagnostics, Genmark Diagnostics Inc continues to drive innovation and shape the future of diagnostic testing.
Genmark Diagnostics Inc has achieved several significant milestones. The company has consistently demonstrated its commitment to innovation and excellence in the field of molecular diagnostics. Notably, Genmark Diagnostics Inc received FDA clearance for its ePlex® Blood Culture Identification Gram-Negative (BCID-GN) Panel, offering rapid and accurate identification of bloodstream infections caused by gram-negative bacteria. In addition, the company has successfully expanded its global presence by obtaining regulatory approvals and entering strategic partnerships in various regions. Genmark Diagnostics Inc has also received recognition for its pioneering technologies and has been honored with prestigious industry awards. These achievements showcase the company's dedication to transforming patient care through cutting-edge diagnostic solutions.
Genmark Diagnostics Inc is primarily present in the United States.
Genmark Diagnostics Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy focused on developing and delivering high-impact molecular diagnostic solutions, Genmark aims to address critical testing needs in the healthcare industry. By leveraging advanced technologies and expertise, the company strives to enhance patient care through accurate and timely diagnostics. Genmark Diagnostics Inc's dedication to driving meaningful advancements in molecular testing and improving patient outcomes stands as a testament to their commitment to excellence in the field of diagnostic medicine.
Genmark Diagnostics Inc is a leading company in molecular diagnostics that offers innovative solutions for healthcare. The company was founded in 1993 and is headquartered in Carlsbad, California. Genmark specializes in the development of molecular diagnostic devices and test kits for medical diagnostics. Its business model includes the sale of diagnostic devices, development and sale of test kits, and diagnostic-related services. Genmark offers two diagnostic systems, the XT-8 and ePlex, which provide fast and accurate diagnosis of infectious diseases and genetic mutations. In addition, the company offers a wide range of test kits for various infections and provides diagnostic services such as clinical consultation and training. Genmark is also actively involved in research and development of new diagnostic devices and test kits tailored to customer and patient needs. Overall, the company aims to offer innovative solutions and services in healthcare, focusing on rapid and accurate diagnosis of infections and genetic mutations.
Il fatturato non può essere attualmente calcolato per Genmark Diagnostics.
Il profitto per Genmark Diagnostics non può essere attualmente calcolato.
Il P/E per Genmark Diagnostics non può essere attualmente calcolato.
L'indicatore Price-to-Sales (P/S) per Genmark Diagnostics non può essere calcolato al momento.
Il Quality Score AlleAktien per Genmark Diagnostics è 4/10.
L'ISIN di Genmark Diagnostics è US3723091043. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Genmark Diagnostics è A1CVZA. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Genmark Diagnostics è GNMK. Con questo simbolo di borsa vengono negoziate le azioni Genmark Diagnostics in borsa.
Azione Genmark Diagnostics
Gruppo di pari di Genmark Diagnostics
Genmark Diagnostics FIGI
Altre metriche e analisi di Genmark Diagnostics in Deep Dive.
La nostra analisi azionaria dell'azione Genmark Diagnostics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Genmark Diagnostics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: